 NEW YORK, March 24, 2021 GLOBE NEWSWIRE -- Mustang Bio, Inc. Mustang NASDAQ: MBIO, a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2020. 